Aligos Therapeutics (ALGS) Other Operating Expenses (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Other Operating Expenses for 8 consecutive years, with $221000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses fell 81.69% year-over-year to $221000.0; the trailing twelve-month figure through Jun 2026 stood at $2.9 million (down 23.1% YoY), and the FY2025 full-year result was $3.9 million, down 10.99% from the prior year.
• Other Operating Expenses fell to $221000.0 in Q2 2026 per ALGS's latest filing, from $811000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $1.6 million in Q1 2024 and bottomed at -$5000.0 in Q1 2022.
• Historically, Other Operating Expenses has averaged $802944.4 across 5 years, with a median of $862500.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses slumped 104.5% in 2022, then soared 20140.0% in 2023.
• Over 5 years, Other Operating Expenses stood at $845000.0 in 2022, then sank by 71.12% to $244000.0 in 2023, then soared by 134.84% to $573000.0 in 2024, then jumped by 30.89% to $750000.0 in 2025, then slumped by 70.53% to $221000.0 in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $221000.0, $811000.0, and $750000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.